Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C] HQP1351 After a Single Oral 30mg (100µCi) Dose in Healthy Chinese Male Subjects

NCT04126707 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT04126707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04126707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C] HQP1351 After a Single Oral 30mg (100µCi) Dose in Healthy Chinese Male Subjects
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 19, 2019
Completion date
January 13, 2020
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia (cml)